Literature DB >> 9925788

NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: molecular insights into its biological functions.

W Schüler1, K Wecker, H de Rocquigny, Y Baudat, J Sire, B P Roques.   

Abstract

The HIV-1 regulatory protein Vpr (96 amino acid residues) is incorporated into the virus particle through a mechanism involving its interaction with the C-terminal portion of Gag. Vpr potentiates virus replication by interrupting cell division in the G2 phase and participates in the nuclear transport of proviral DNA. The domain encompassing the 40 C-terminal residues of Vpr was shown to be involved in cell cycle arrest and binding of nucleocapsid protein NCp7, and suggested to promote nuclear provirus transfer. Accordingly, we show here that the synthetic 52-96 but not 1-51 sequences of Vpr interact with HIV-1 RNA. Based on these results, the structure of (52-96)Vpr was analysed by two-dimensional 1H-NMR in aqueous TFE (30%) solution and refined by restrained molecular dynamics. The structure is characterized by a long (53-78) amphipathic alpha-helix, followed by a less defined (79-96) C-terminal domain. The Leu60 and Leu67 side-chains are located on the hydrophobic side of the helix, suggesting their involvement in Vpr dimerization through a leucine zipper-type mechanism. Accordingly, their replacement by Ala eliminates Vpr dimerization in the two hybrid systems, while mutations of Ile74 and Ile81 have no effect. This was confirmed by gel filtration measurements and circular dichroism, which also showed that the alpha-helix still exists in (52-96)Vpr and its Ala60, Ala67 mutant in the presence and absence of TFE. Based on these results, a model of the coiled-coil Vpr dimer has been described, and its biological relevance as well as that of the structural characteristics of the 52-96 domain for the different functions of Vpr, including HIV-1 RNA binding, are discussed. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9925788     DOI: 10.1006/jmbi.1998.2381

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  34 in total

1.  Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73.

Authors:  B E Sawaya; K Khalili; J Gordon; A Srinivasan; M Richardson; J Rappaport; S Amini
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Efficient DNA transfection mediated by the C-terminal domain of human immunodeficiency virus type 1 viral protein R.

Authors:  A Kichler; J C Pages; C Leborgne; S Druillennec; C Lenoir; D Coulaud; E Delain; E Le Cam; B P Roques; O Danos
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A.

Authors:  M Hrimech; X J Yao; P E Branton; E A Cohen
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

5.  Simultaneous positive and purifying selection on overlapping reading frames of the tat and vpr genes of simian immunodeficiency virus.

Authors:  A L Hughes; K Westover; J da Silva; D H O'Connor; D I Watkins
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G(2) cell cycle arrest.

Authors:  M P Sherman; C M de Noronha; D Pearce; W C Greene
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 8.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 9.  HIV-1 Vpr: mechanisms of G2 arrest and apoptosis.

Authors:  Joshua L Andersen; Erwann Le Rouzic; Vicente Planelles
Journal:  Exp Mol Pathol       Date:  2008-04-25       Impact factor: 3.362

10.  The C-terminal domain of the HIV-1 regulatory protein Vpr adopts an antiparallel dimeric structure in solution via its leucine-zipper-like domain.

Authors:  Sarah Bourbigot; Hervé Beltz; Jérôme Denis; Nelly Morellet; Bernard P Roques; Yves Mély; Serge Bouaziz
Journal:  Biochem J       Date:  2005-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.